Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / ICLR - ICON partners with Cytocom in a Phase 3 trial for Crohn's disease

ICLR - ICON partners with Cytocom in a Phase 3 trial for Crohn's disease

ICON plc
ICON Public Limited (ICLR) has entered into an agreement with the privately held clinical-stage biotech company, Cytocom to manage the company’s Phase 3 clinical trial for its lead drug candidate, CYTO-201 in Crohn's disease."CYTO-201 is the program's lead clinical asset and we are pleased to have ICON as our CRO partner, given the company's proven expertise and track record of clinical excellence,” noted Cytocom CEO Michael K. Handley.Last October, Cleveland BioLabs (NASDAQ:CBLI) surged in the premarket after the company announced an agreement for a merger with Cytocom. The deal was expected to close in Q1 2021.

For further details see:

ICON partners with Cytocom in a Phase 3 trial for Crohn's disease
Stock Information
Company Name: ICON plc
Stock Symbol: ICLR
Market: NASDAQ
Website: iconplc.com
Menu
ICLR ICLR Quote ICLR Short ICLR News ICLR Articles ICLR Message Board
Get ICLR Alerts

News, Short Squeeze, Breakout and More Instantly...